Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes

 This study was supported by a grant from the Council on Clinical Cardiology of the American Heart Association, Dallas, Texas; the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program is funded in part by the Merck Schering-Plough partnership, North Wales, Pennsylvania. Data collection and management were performed by Outcome Sciences, Cambridge, Massachusetts. The analysis of registry data were performed at Duke Clinical Research Institute, Durham, North Carolina, which also receives funding from the American Heart Association. The sponsor was not involved in the management, analysis, or interpretation of data or the preparation of the manuscript.

 Dr. Cannon has received research grants/support from Accumetrics (San Diego, California), AstraZeneca (London, UK), Bristol-Myers Squibb/Sanofi Partnership (Bridgewater, New Jersey), GlaxoSmithKline (Philadelphia, Pennsylvania), Intekrin Therapeutics (Los Altos, California), Merck (Whitehouse Station, New Jersey), Merck/Schering Plough Partnership, Novartis (East Hanover, New Jersey), and Takeda (Osaka, Japan). He serves as a clinical advisor and equity partner in Automedics Medical Systems (San Diego, California). He also serves as the chair of the Get With The Guidelines Steering Science Subcommittee; Dr. Fonarow has received research funding from GlaxoSmithKline and Medtronic (Minneapolis, Minnesota), served as consultant, and/or received honorarium from Bristol Myers Squibb (Princeton, New Jersey), GlaxoSmithKline, Medtronic, Merck, Pfizer (New York, New York), Sanofi-Aventis (Paris, France), and Schering Plough (Kenilworth, New Jersey) and serves as the chair of the Get With The Guidelines Steering Committee of the American Heart Association; Dr. Bhatt has received research grants from Bristol Myers Squibb, Sanofi Aventis, Heartscape (Columbia, Maryland), the Medicines Company (Parsippany, New Jersey), Eisai (Tokyo, Japan), and Ethicon (New Brunswick, New Jersey) and has served as a consultant to Arena (San Diego, California), Astellas (Tokyo, Japan), AstraZeneca, Bayer (Leverkusen, Germany), Bristol Myers Squibb, Cardax (Honolulu, Hawaii), Centocor (Horsham, Pennsylvania), Cogentus (Palo Alto, California), Daiichi Sankyo (Tokyo, Japan), Eisai, Eli Lilly (Indianapolis, Indiana), GlaxoSmithKline, Johnson & Johnson (New Brunswick, New Jersey), McNeil (New Brunswick, New Jersey), Medtronic, Millennium (Cambridge Massachusetts), Molecular Insights (Cambridge, Massachusetts), Otsuka (Rockville, Maryland), Paringenix (Tucson, Arizona), PDL (Redwood City, California), Philips (Amsterdam, Netherlands), Portola (San Francisco, California), Sanofi Aventis, Schering Plough, Takeda, the Medicines Company, and Vertex (Cambridge, Massachusetts); and Dr. Peacock has received research funding from Abbott (Abbott Park, Illinois), Biosite (San Diego, California), Brahms (Annapolis, Maryland), Cothera (San Mateo, California) Heartscape, Inovise (Beaverton, Oregon), Inverness (Waltham, Massachusetts), EKR (Bedminster, New Jersey), the Medicines Company, has served on the scientific advisory board for Abbott, Beckman-Coulter (Fullerton, California), Biosite, Heartscape, Inovise, Ortho-Clinical Diagnostics (Rochester, New York), and the Medicines Company, and has been on the speaker's bureau of Abbott and Biosite.

PII: S0002-9149(09)01253-3

doi: 10.1016/j.amjcard.2009.06.027